Press Releases

2015

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

Visterra 10.05.2015

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

Visterra 10.05.2015

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

Visterra 09.09.2015

Loading